VIDEO: 3:26 Minutes
Even when people are not experiencing symptoms, it is important to consider the outcomes research when deciding whether or not to treat.
Next, it is also important to better understand which patients benefit most from treatment at this phase.
We are learning more about how to stratify patient risk groups so that patients and providers can take a systematic, evidence-based approach to their treatment decisions.
Mark Bustoros, MD, of the Dana Farber Cancer Institute, gives his perspective on whether to treat patients with asymptomatic myeloma to delay disease progression. He also provides insight into which of these patients should be treated.